Introduction {#S1}
============

Nowadays, solid organ transplantation is considered the treatment of choice for many people with severe chronic diseases, but still there is a shortage of organs available for donation ([@B1]). Moreover, the costs of organ transplantation include transplant evaluation and testing, transplant surgery, follow-up care, and medication. The average reported cost of solid organ transplant ranges from \$260,000 for a single kidney transplant to over \$1.2 million dollars for combined heart and lung transplants ([@B2]).

One of the greatest challenges facing the field of organ transplantation today is continuous increasing of immunosuppressant utilization and expenditure ([@B3]). Since it is well known that immunosuppression is required for the lifetime of a solid organ transplant to prevent rejection, the cost of these medications is constant concern not only for health insurance funds but especially for those lacking long-term insurance coverage ([@B4], [@B5]).

Not only oral immunosuppressive agents and other necessary drugs but also insurance expenses can cost patients up to \$2,500.00 per month, depending of patient clinical condition and other factors ([@B5]). In the United States, annual cost of medications accounts between \$10,000 and \$14,000 per patient ([@B6]).

Induction therapy is given at the time of transplantation, while later on various combination of orally taken agents are necessary. Current recommended protocols in the patients subjected to solid organ transplantation include calcineurin inhibitors (tacrolimus or cyclosporine) and antiproliferative agents (mycophenolate mofetil or azathioprine), with or without regimens of corticosteroids ([@B4], [@B7], [@B8]).

Tacrolimus is the first-line treatment according to the Kidney Disease Improving Global Outcomes Transplant Work Group ([@B4]) and is also commonly used in the liver and heart transplantation ([@B3], [@B9]). It was first developed as a twice-daily oral formulation (tacrolimus-BID), while once-daily tacrolimus (tacrolimus-OD) appeared in order to improve drug compliance and lower pill burden ([@B10]). It was shown that tacrolimus-OD ensure better drug compliance comparing with tacrolimus-BID, associated with improved graft outcome, glucose tolerance, and lipid profile ([@B11], [@B12]).

In our previous study, it was shown that immunosuppressive drugs are significant factor of the total cost of organ transplantation ([@B13]). Similar results were obtained in some other studies ([@B3], [@B14]--[@B16]).

Since tacrolimus has been the cornerstone of the standard immunosuppressive regimen in solid organ transplant recipients, the aim of our study was to characterize its utilization and expenditure in Serbian population of patients.

Materials and Methods {#S2}
=====================

Retrospective cross-sectional study was performed during a 3-year period (from 2013 to 2015). Anatomical Therapeutic Chemical Classification/Defined Daily Doses (ATC/DDD) international system for classification and consumption of drugs according to the WHO methodology was used for tacrolimus consumption ([@B17]). In the ATC classification, drugs are assorted into different groups in accordance with their mechanism of action and according to the therapeutic, pharmacological, and chemical properties. DDD values are the average maintenance dose per day for a drug when it is applied in its main indication, concerning average adult. DDD per 1,000 inhabitants/day is a measurement unit used for tacrolimus consumption. DDD used for oral application of tacrolimus was 5 mg, while ATC code was L04AD02. Calculations were done according the following equation: $$\text{DDD}/1,000\text{~inhabitans}/\text{day} = \frac{\text{Amount~of~drug~}(\text{mg})\text{~sold~in~1~year}}{\text{DDD}(\text{mg}) \times 365\text{~days} \times \text{Number~of~people}} \times 1,000.$$

Tacrolimus utilization and expenditure in Serbia is based on official data released by the Medicines and medical devices agency of Serbia and national Health insurance fund ([@B18]). In accordance with the Law on Medicines in Serbia, Medicines and medical devices agency of Serbia collects and processes data on marketing and consumption of medicinal products in our country and publishes them annually. These publications contain health, economic, and statistical indicators concerning medicinal product use in Serbia.

On the other hand, data concerning the number of renal, liver, and heart organ transplantations, number of deceased/living donors, and the number of all new solid organ transplants from deceased/living donors per million population per year are based on the data obtained from Department of Biomedicine, Ministry of Health, Republic of Serbia ([@B19]). The number of total people in Serbia was 7,186,862, according to latest census of population in 2011 ([@B20]).

Microsoft Office Excel 2007 was used for statistical analysis. Trend analysis was used for data processing concerning observed period from 2013 to 2015.
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Results {#S3}
=======

During the observed 3-year period, 269 patients were transplanted (185 recipients with deceased donors and 84 recipients with living donors) (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The most of transplant patients received a renal cadaveric graft (74, 40, and 11 in 2013, 2014, and 2015, respectively). Total number of cadaveric donors was 41, 22, and 18 in 2013, 2014, and 2015, respectively.
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In Serbia, the number of all new solid organ transplants with deceased donors per million population per year continually decreased from 13.22 to 6.12 during the 3-year period (2013--2015) (Figure [3](#F3){ref-type="fig"}). The number of new solid organ transplants with living donors per million population per year was similar during the 3-year period (from 4.17 to 3.90, in 2013 and 2015, respectively).
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On the other hand, Figure [4](#F4){ref-type="fig"} shows consumed amounts of tacrolimus based on DDD and DDD/1,000 inhabitants per day units during examined 3-year period. The consumption of tacrolimus was constantly increasing (from 0.051 DDD/1,000 inhabitants per day to 0.069 DDD/1,000 inhabitants per day; in 2013 and 2015, respectively). Also, the total cost of tacrolimus was constantly increasing (Figure [5](#F5){ref-type="fig"}); from 2013 to 2015 total cost was increased for 22.92%, i.e., from 1,206,816€ to 1,483,472€.
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Discussion {#S4}
==========

The public spending on pharmaceuticals in Serbia was doubled in less than a decade (from 2004 to 2012) ([@B21]--[@B23]). This growth was recorded mostly due to expenditure of statins, novel platelet aggregation inhibitors, monoclonal antibodies, combined preparations indicated in asthma, and chronic obstructive pulmonary disease, as well as immunosuppressive drugs like tacrolimus. Therefore, the main working hypothesis of our study was the positive trend in the consumption of tacrolimus in our country. According to that the aim of our study was to characterize its utilization, as well as expenditure in Serbian population of patients during the observed 3-year period, from 2013 to 2015.

Utilization of tacrolimus in Australian population was 0.248 DDD/1,000 inhabitants per day in 2013 ([@B3]). The total consumption of tacrolimus in Serbia was equal to 20.56% of the consumption of tacrolimus in Australia population in the same year. On the other hand, in year 2012 number of new renal transplants per million population per year was about 55 in Australian population ([@B3]), whereas in our country it accounted for 13.22 for all solid organ transplantation in year 2013. The number of donors in our country was continually decreasing.

However, number of patients on waiting lists, not only in our country, reflects difficult situation in lacking the suitable organ, concerning various transplant systems with different national policies ([@B24]). In Europe, if patients from Iceland, Norway, and Turkey are added, 86,000 patients were on the waiting lists in 2013 (for a total population of 588 million inhabitants) ([@B24]). However, many patients die while officially have been placed on these waiting lists. Existence of the European organ exchange organizations (Eurotransplant, Scandiatransplant, and South Alliance for Transplants) is very important for increasing the number of donors ([@B24], [@B25]). Serbia is in the phase of accession to the Eurotransplant, what should reduce waiting lists and increase the number of donors and transplants realized.

Renal transplantation is most often performed in comparison to other solid organ transplants (liver, heart) ([@B3]). Costs per one transplanted patient in Serbia for a 10-year period were calculated to be €48,949 ([@B26]). Its Gross Domestic Product (GDP) per capita is \$5,348.29 in 2016 year. Although their GDP/capita is not so high comparing with other countries from the Western World (\$12,090.66 in 2016 comparing with 15,893.86 in 2008), Croatian health-care system affords costly procedures such a kidney transplants: their number of 50 transplants per million population is among the top countries of Europe ([@B27]). Therefore, the performance of the countries such as Croatia shows that GDP per capita need not to be a dominating factor in the successful solid organ transplantation. According to this report ([@B27]), Serbia is on the last place by the number of renal transplants per million population per year in 2016.

As it was mentioned, the cost of immunosuppressive drugs is constant concern since they are required for the lifetime in patients subjected to solid organ transplantation. According to the data of US United Network for Organ Sharing, costs are more than \$262,000 just for the first year after kidney transplantation ([@B28]). The total monthly costs of Cellcept^®^, Prograf^®^, Prednisone^®^, and Myfortic^®^ were \$1,064, \$1,340, \$12, and \$806, respectively. The 2-year costs of four different immunosuppressive drugs (sirolimus, everolimus, cyclosporine, or tacrolimus) have been shown to vary between €26,732 and €49,978 ([@B29]). In Iran, the total cost of renal transplantation procedure was \$9,224, while the immunosuppressive therapy accounted for even 65.8%, only in the first year ([@B30]).

In Croatia, the total cost of tacrolimus was 2,156,521€ in 2013; 1,942,018€ in 2014; and 2,449,061€ in 2015. The consumption of tacrolimus was higher in the same period than in Serbia (0.19, 0.15, and 0.18 DDD/1,000 inhabitants per day; in 2013, 2014, and 2015, respectively) ([@B31]). Therefore, in 2015, the consumption of tacrolimus was 2.6-fold higher in Croatia comparing with Serbia, while its expenditure was 1.65-fold higher in Croatia in comparison to our country.

The cost and consequences of medication non-adherence should also be taken into account when the price of immunosuppression and of solid organ transplantation, as a whole, are considered ([@B32]). The introduction to the market of generic formulations will probably decrease the financial burden concerning immunosuppresive agents. However, costs concerning conversion, as well as initial expenses due to laboratory monitoring should be taken into account ([@B33]). Other costs that should be included are those concerning adverse effects, episodes of rejection, etc. The fact that there is relatively small market of transplantation can also explain escalating costs of therapy. Therefore, although the number of all new solid organ transplants per million population per year continually decreased in Serbia, the prevalence rate of the transplantation is constantly increasing due to the fact that transplant recipients' lifespan and long-term allograft survival are improved. Also, in our country transplantologists also take care of the transplant recipients who were subjected to transplantation in other countries. All of this leads to expectations that tacrolimus utilization and expenditure will most likely to continue to grow.

The limitation of the study is that we have not been able to evaluate the trend in the consumption of other immunosuppressants used in solid organ transplantation in our country (azathioprine, corticosteroids, cyclosporine, sirolimus, everolimus, mycophenolic acid, biologicals) and compared it with tacrolimus. Namely, these drugs have numerous other indications and it has not been possible, due to the nature of the available data concerning their consumption, to include them in this study. However, it is highly recommended that Cost-Effectiveness Analysis studies between different immunosuppressive drugs used in Serbian solid organ transplant recipients would be performed in the future.

Conclusion {#S5}
==========

In spite downward trend in the number of solid organ transplants, tacrolimus consumption and expenditure increased in the examined period from 2013 to 2015 in Serbia. Since tacrolimus is a high-cost and life-preserving drug, its increasing utilization and expenditure will most likely continue consuming an enhancing share of Serbian pharmaceutical expenditure, as well as its health care, as a whole.
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